Luke Walker

1.9k total citations
39 papers, 489 citations indexed

About

Luke Walker is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Luke Walker has authored 39 papers receiving a total of 489 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 11 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Luke Walker's work include HER2/EGFR in Cancer Research (21 papers), Cancer Treatment and Pharmacology (17 papers) and Advanced Breast Cancer Therapies (12 papers). Luke Walker is often cited by papers focused on HER2/EGFR in Cancer Research (21 papers), Cancer Treatment and Pharmacology (17 papers) and Advanced Breast Cancer Therapies (12 papers). Luke Walker collaborates with scholars based in United States, Japan and Germany. Luke Walker's co-authors include Diana F. Hausman, Antonio Jimeno, Alexander I. Spira, Daniel W. Bowles, Charles M. Rudin, Keisuke Shirai, Ian D. Schnadig, Mark D. Kochenderfer, Minsig Choi and Benjamin Levy and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

Luke Walker

39 papers receiving 489 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Luke Walker United States	10	272	255	253	90	59	39	489
Mike Lau United Kingdom	9	197 0.7×	138 0.5×	173 0.7×	29 0.3×	26 0.4×	25	351
Julio A. Peguero United States	12	368 1.4×	241 0.9×	133 0.5×	28 0.3×	27 0.5×	49	517
József Lövey Hungary	12	168 0.6×	153 0.6×	90 0.4×	17 0.2×	59 1.0×	46	406
Christian P. Turtschi Switzerland	4	200 0.7×	166 0.7×	336 1.3×	80 0.9×	18 0.3×	4	486
Kanchan Puttaswamy United States	7	264 1.0×	94 0.4×	197 0.8×	33 0.4×	32 0.5×	10	718
Hisao Uejima Japan	11	371 1.4×	374 1.5×	127 0.5×	14 0.2×	44 0.7×	22	549
J.M. Sánchez-Torres Spain	13	614 2.3×	428 1.7×	150 0.6×	42 0.5×	19 0.3×	21	772
James D. Peyton United States	10	200 0.7×	145 0.6×	175 0.7×	20 0.2×	10 0.2×	27	363
Serena Ricciardi Italy	11	342 1.3×	287 1.1×	178 0.7×	26 0.3×	30 0.5×	27	545
F. Eskens Netherlands	10	244 0.9×	189 0.7×	153 0.6×	40 0.4×	26 0.4×	20	366

Countries citing papers authored by Luke Walker

Since Specialization

Citations

This map shows the geographic impact of Luke Walker's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luke Walker with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luke Walker more than expected).

Fields of papers citing papers by Luke Walker

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luke Walker. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luke Walker. The network helps show where Luke Walker may publish in the future.

Co-authorship network of co-authors of Luke Walker

This figure shows the co-authorship network connecting the top 25 collaborators of Luke Walker. A scholar is included among the top collaborators of Luke Walker based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luke Walker. Luke Walker is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Choudhury, Noura J., Prantesh Jain, Afshin Dowlati, et al.. (2023). 698P Interim results from a phase I/II study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN). Annals of Oncology. 34. S486–S486. 5 indexed citations

Lee, Anthony, et al.. (2023). Pharmacokinetics and Safety of Tucatinib in Healthy Japanese and Caucasian Volunteers: Results From a Phase Ⅰ Study. Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics. 54(5). 187–196. 1 indexed citations

Lee, Anthony, et al.. (2022). Evaluation of Safety and Clinically Relevant Drug–Drug Interactions with Tucatinib in Healthy Volunteers. Clinical Pharmacokinetics. 61(10). 1417–1426. 11 indexed citations

Lee, Anthony, et al.. (2022). The Pharmacokinetics and Safety of Tucatinib in Volunteers with Hepatic Impairment. Clinical Pharmacokinetics. 61(12). 1761–1770. 5 indexed citations

Hurvitz, Sara A., Nadia Harbeck, Linda T. Vahdat, et al.. (2021). 126TiP HER2CLIMB-02: Tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer. Annals of Oncology. 32. S75–S75. 3 indexed citations

Strickler, John H., Kimmie Ng, Andrea Cercek, et al.. (2020). 523TiP MOUNTAINEER: Open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer. Annals of Oncology. 31. S460–S461. 1 indexed citations

Masuda, Norikazu, Sara A. Hurvitz, Linda T. Vahdat, et al.. (2020). 67TiP HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally-advanced or metastatic HER2+ breast cancer. Annals of Oncology. 31. S1267–S1268. 2 indexed citations

Hurvitz, Sara A., Linda T. Vahdat, Nadia Harbeck, et al.. (2020). 353TiP HER2CLIMB-02: A randomized, double-blind, phase III study of tucatinib or placebo with T-DM1 for unresectable locally advanced or metastatic HER2+ breast cancer. Annals of Oncology. 31. S390–S390. 4 indexed citations

Lee, Anthony, et al.. (2020). Tucatinib Inhibits Renal Transporters OCT2 and MATE Without Impacting Renal Function in Healthy Subjects. The Journal of Clinical Pharmacology. 61(4). 461–471. 22 indexed citations

10.

Metzger, Otto, José Pablo Leone, T. Li, et al.. (2020). Phase I dose-escalation trial of tucatinib in combination with trastuzumab in patients with HER2-positive breast cancer brain metastases. Annals of Oncology. 31(9). 1231–1239. 35 indexed citations

11.

Bachelot, Thomas, et al.. (2019). A randomized, double-blinded, controlled study of tucatinib (ONT-380) vs placebo in combination with capecitabine (C) and trastuzumab (T) in patients with pretreated HER2+ unresectable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB). Annals of Oncology. 30. iii63–iii64. 2 indexed citations

12.

Vo, Alex, et al.. (2017). Evaluation of drug-drug interactions (DDI) between tucatinib and capecitabine (C) in patients with advanced HER2+ metastatic breast cancer from a phase 1b study. Annals of Oncology. 28. v98–v98. 1 indexed citations

13.

Bowles, Daniel W., Mark D. Kochenderfer, Allen Lee Cohn, et al.. (2016). A Randomized, Phase II Trial of Cetuximab With or Without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients With Metastatic Colorectal Carcinoma. Clinical Colorectal Cancer. 15(4). 337–344.e2. 37 indexed citations

14.

Jimeno, Antonio, Julie E. Bauman, Charles Weissman, et al.. (2015). A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. Oral Oncology. 51(4). 383–388. 66 indexed citations

15.

Walker, Luke, et al.. (2015). Developing and Implementing Dynamic Partial Reconfiguration for Pre-Emptible Context Switching and Continuous End-To-End Dataflow Applications. The University of Bath Online Publications Store (The University of Bath). 2 indexed citations

16.

Levy, Benjamin, Alexander I. Spira, Daniel Becker, et al.. (2014). A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology. 9(7). 1031–1035. 42 indexed citations

17.

Bowles, Daniel W., Neil Senzer, Diana F. Hausman, et al.. (2014). A multicenter phase 1 study of PX-866 and cetuximab in patients with metastatic colorectal carcinoma or recurrent/metastatic squamous cell carcinoma of the head and neck. Investigational New Drugs. 32(6). 1197–1203. 19 indexed citations

18.

Jimeno, Antonio, Keisuke Shirai, Minsig Choi, et al.. (2014). A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer. Annals of Oncology. 26(3). 556–561. 82 indexed citations

19.

Bowles, Daniel W., Neil Senzer, Julie R. Brahmer, et al.. (2013). A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. British Journal of Cancer. 109(5). 1085–1092. 53 indexed citations

20.

Ravel, A., et al.. (1999). Endovascular Doppler Guide Wire in Renal Arteries. Investigative Radiology. 34(8). 530–530. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact